The Nasdaq staged a more than 2 percent rally back from the brink of correction territory Tuesday in the biggest one day turnaround in five years.» Read More
Amgen's stock fell sharply after the company said it had discontinued a key clinical trial of its drug Vectibix in combination with other drugs as an initial treatment for colon cancer. The report helped boost shares of other drugmakers such as ImClone Systems, which makes a competing drug Erbitux.
Stocks are edging higher ahead of the opening. Existing home sales data at 10 am New York time could influence direction but for now investors face a flurry of Friday morning corporate news headlines.
The U.S. Food and Drug Administration on Friday issued a public health advisory for three widely-used drugs manufactured by Amgen for the treatment of anemia.
Today Cramer gives advice on Amgen, Cisco and more. He's also banning two stocks from the Lightning Round!
John from Florida asked about Amgen. This stock is hanging around a 52 week low and was down 4% yesterday on the news that the SEC is probing their anemia drug Aranesp. Given the unstable market conditions we have, I am wondering if 4% was an overreaction and if AMGN is a buy here?
While no one was looking shares of Amgen, the world's biggest biotech company (by sales, not market cap--Genentech is #1 there) have fallen from nearly $76 on January 22nd to the low-60s. What happened? In a nutshell, the company has been buffeted by safety, reimbursement and competitive concerns about its biggest drug franchise known as the acronym EPO.
Cramer tells you what to do with AT&T, Retail Ventures, Choice Hotels and more.
The world's largest biotechnology company posted a net profit of $833 million, or 71 cents a share, compared with $824 million, or 66 cents a share, a year ago.
The findings on Aranesp and colon cancer treatment Vectibix were released late on Thursday, as the world's largest biotechnology company reported a marginal increase in fourth-quarter profit.
Wall Street is undecided so far on where it will start the day though early earnings news and housing data could help set the tone. For now, eBay's strong profits and big stock move is a bright spot lifting the Nasdaq, which bounced higher on a tech rebound yesterday. The Dow, fresh off its 26th high since October, is flattish.
The diversified health-care company earned $2.17 billion, or 74 cents a share in the fourth quarter, compared with $2.1 billion, or 70 cents, a year earlier.
Genentech, a maker of medical biotechnology products, reported earnings of 61 cents a share for the fourth quarter, better than analysts estimates of 56 cents.
You’ll find some of the most influential figures in modern healthcare in San Francisco today, gathered together for the 25th Annual J.P. Morgan Healthcare Conference. This year, 6500 people are attending, including CNBC’s Mike Huckman who is sifting through volumes of data. In a "First on CNBC," Huckman spoke with James Sabry, M.D./Ph. D., the CEO of Cytokinetics.
Stocks closed higher after another volatile day as gains in technology stocks and a huge drop in oil prices boosted the major averages.
Amgen and Cytokinetics announced a collaboration to develop heart failure drugs that could yield smaller Cytokinetics more than $600 million depending on development success.